Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 24, 2017
Pharmacy Choice - Pharmaceutical News - King, Collins, Durbin, Portman, Brown, Capito Introduce Bipartisan Bill to Expand Access to Substance Abuse Treatment Under Medicaid - November 24, 2017

Pharmacy News Article

 5/19/17 - King, Collins, Durbin, Portman, Brown, Capito Introduce Bipartisan Bill to Expand Access to Substance Abuse Treatment Under Medicaid

WASHINGTON, May 18 The office of Sen. Angus S. King Jr., I-Maine, issued the following news release:

U.S. Senators Angus King (I-Maine), Susan Collins (R-Maine), Dick Durbin (D-Ill.), Rob Portman (R-Ohio), and Shelley Moore Capito (R-W.Va.) have introduced the Medicaid Coverage for Addiction Recovery Expansion (Medicaid CARE) Act, bipartisan legislation that would expand access to substance abuse treatment for tens of thousands of Medicaid beneficiaries across the country.

The Medicaid CARE Act would increase addiction treatment services to help combat the heroin and prescription opioid epidemic by modifying the Medicaid Institutions for Mental Disease (IMD) Exclusion, an arcane policy created in 1965 that limits Medicaid coverage for substance abuse treatment to facilities with less than 16 beds. The Medicaid CARE Act would lift this outdated barrier by expanding Medicaid coverage to pay for up to 40 treatment beds at larger substance abuse treatment facilities.

Senators King and Durbin introduced a similiar bill last year.

"Expanding access to treatment facilities is critical to helping Maine people struggling with addiction. It's no exaggeration to say that an available bed at a treatment facility could mean the difference between life and death. In fact, one of the most tragic circumstances is when someone is ready to seek help and they're turned away because of a lack of resources," Senator King said. "Today, outdated federal rules are limiting the availability of treatment and standing in the way of these potentially lifesaving opportunities. By increasing this decades-old cap, this legislation will allow treatment facilities to do what they do best - extend a helping hand to more people who are in need of it."

"Our nation's opioid and heroin epidemic has devastated countless families and communities across the country and has hit Maine particularly hard," said Senator Collins. "As we look for ways to address this burgeoning public health crisis, we must identify and correct outdated policies like the IMD exclusion that unintentionally block access to lifesaving substance abuse treatment. By improving access to treatment opportunities, our legislation will help provide hope and healing to those struggling with addiction."

The IMD Exclusion prohibits the use of federal Medicaid funding for any care provided to patients 22-64 years old in residential mental health or substance abuse facilities larger than 16 beds. This policy was created over 50 years ago to discourage the mass warehousing of those with mental illness. But as understanding and treatment options for addiction have improved, this outdated rule continues to pose a barrier. It also violates substance use disorder treatment parity requirements by unfairly discriminating against Medicaid beneficiaries. This policy is no longer justified, and stakeholders, such as the Surgeon General and National Governors Association, agree that this policy poses a burden to care.

The Medicaid CARE Act modifies the IMD Exclusion to allow Medicaid coverage for up to 40 beds in appropriately accredited "residential addiction treatment facilities" for up to 60 consecutive days for adults with substance use disorders. The bill allows individuals receiving addiction treatment in such a facility to maintain Medicaid coverage for other medical services, which are currently ineligible under the IMD Exclusion.

The legislation also establishes a new $50 million youth inpatient addiction treatment grant program to fund facilities that provide substance use disorder treatment services to underserved, at-risk Medicaid beneficiaries who are younger than age 21, with an emphasis on rural communities. In addition, the bill would increase flexibility for pregnant and postpartum women who are seeking treatment, and would allow them to access the services they need to ensure positive birth outcomes. This legislation builds off a bipartisan letter that Senators King, Durbin, Collins, Portman, Brown, Capito and 23 other Senators sent in August 2016 to the Centers for Medicare and Medicaid Services (CMS) pushing for greater flexibility on IMD Exclusion to expand access to treatment.

U.S. Representative Bill Foster (D-Ill.) will be introducing the House companion version of this bill.

The bill is endorsed by the National Council for Behavioral Health, Treatment Communities for America, Mental Health America, National Association of City and County Health Officials, Commission on Accreditation for Residential Facilities, and Joint Commission.



Targeted News Service

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Nov 29: Influenza 2017-2018: An Update on Prevention and Treatment
Nov 30: School is Out! Life is in Session: The Importance of Professional Development in Pharmacy
Dec 01: Anticoagulants: The Rapidly Changing Landscape
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415